REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.…
Industry Peers
BiotechnologyKey Statistics
About Regeneron Pharmaceuticals (NASDAQ: REGN)
›
Regeneron Pharmaceuticals (NASDAQ: REGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15,410 employees.
The shares were at 930.21 USD on 20 November 2026, up 43.3% over 52 weeks. Its 52-week range is 591.52 USD to 991.73 USD: the price is 6.2% below the high and 57.3% above the low.
At a market capitalisation of 95.52B USD, it trades at 20.4 times trailing earnings and 13.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 41% for REGN. It pays a dividend yielding 0.40% (it pays out 8% of its earnings), against a median of 1.39% among the dividend payers in that peer group.
Regeneron Pharmaceuticals reports return on equity of 14.4%, an operating margin of 30.4% and revenue up 36.3% year over year.
It holds more cash than debt, a net cash position of 6.59B USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 990.81 USD is 6.5% above the current price. The next earnings report is expected on 28 January 2027.